Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 9/20 | 0.69 |
| ▸ | PGR | P06401 | 6/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.69 |
| ▸ | DRD2 | P14416 | 1/20 | 0.69 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.69 |
| ▸ | LMNA | P02545 | 5/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | AR | P10275 | 2/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.69 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.69 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11249101 | 0.92 | NR3C1 (0.72) | NR3C1PGRMAPTADORA3NR1I2 | |
| SCHEMBL11251406 | 0.92 | NR3C1 (0.72) | NR3C1PGRMAPTADORA3NR1I2 | |
| SCHEMBL11037864 | 0.92 | NR3C1 (0.72) | NR3C1PGRADORA3CYP3A4LMNA | |
| SCHEMBL4102916 | 0.92 | NR3C1 (0.72) | NR3C1PGRADORA3CYP3A4LMNA | |
| SCHEMBL11037205 | 0.91 | NR3C1 (0.83) | NR3C1PGRMAPTADORA3NR1I2 | |
| SCHEMBL11081794 | 0.91 | NR3C1 (0.68) | NR3C1PGRMAPTADORA3NR1I2 | |
| Mometasone Furoate SCHEMBL570073 | 0.89 | CYP3A4 (0.77) | NR3C1PGRMAPTADORA3NR1I2 | |
| SCHEMBL4003694 | 0.89 | NR3C1 (0.68) | NR3C1PGRMAPTADORA3NR1I2 | |
| SCHEMBL4224907 | 0.89 | NR3C1 (0.68) | NR3C1PGRMAPTADORA3NR1I2 | |
| SCHEMBL4003695 | 0.88 | NR3C1 (0.67) | NR3C1PGRMAPTADORA3NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295608-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS | INSIGNIA PHARMACEUTICALS, LLC (US) | 2025-09-25 | — | — | US | claimed |
| US-20250288599-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS | INSIGNIA PHARMACEUTICALS, LLC (US) | 2025-09-18 | — | — | US | claimed |
| EP-3993715-B1 | IMPLANTATION NEEDLE FOR INSERTING A SUBCUTANEOUSLY INSERTABLE ELEMENT INTO A BODY TISSUE | HOFFMANN LA ROCHE (CH) | 2024-04-17 | — | — | EP | claimed |
| US-20230210868-A1 | Methods of Treatment Using ICAM-Modulating Agents | AVM BIOTECHNOLOGY, LLC (US) | 2023-07-06 | — | — | US | claimed |
| EP-2794008-A1 | COMBINATION ANTI-INFLAMMATORY OPHTHALMIC COMPOSITIONS | Insite Vision Incorporated (US) | 2014-10-29 | — | — | EP | claimed |
| US-20130165419-A1 | COMBINATION ANTI-INFLAMMATORY OPHTHALMIC COMPOSITIONS | INSITE VISION INCORPORATED | 2013-06-27 | — | — | US | claimed |
| WO-2013096857-A1 | COMBINATION ANTI-INFLAMMATORY OPHTHALMIC COMPOSITIONS | INSITE VISION INCORPORATED (US) | 2013-06-27 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4646217-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | Stellular Bio, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20240423907-A1 | Improved Nasal Administration of Pharmaceutical Formulations | CYRANO THERAPEUTICS, INC. | 2024-12-26 | — | — | US | disclosed |
| EP-4476217-A1 | MORPHIC FORMS OF CFT7455 AND METHODS OF MANUFACTURE THEREOF | C4 Therapeutics, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| US-20240391912-A1 | MORPHIC FORMS OF CFT7455 AND METHODS OF MANUFACTURE THEREOF | C4 THERAPEUTICS, INC. (US) | 2024-11-28 | — | — | US | disclosed |
| EP-4460284-A1 | IMPROVED NASAL ADMINISTRATION OF PHARMACEUTICAL FORMULATIONS | Cyrano Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| WO-2002045693-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA PHARMA AG (DE) | 2002-06-13 | — | — | WO | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | LUITPOLD PHARMACEUTICALS, INC. | 2001-05-31 | — | — | US | disclosed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165419-A1 | COMBINATION ANTI-INFLAMMATORY OPHTHALMIC COMPOSITIONS | PTGS1, TNF, PTGES | NR3C1 209/4885PGR 749/4885MAPT 2890/4885 |
| US-20010002404-A1 | Fatty acid-pharmaceutical agent conjugates | FABP7, FFAR2, FFAR4 | NR3C1 1759/4885PGR 3268/4885MAPT 1592/4885 |
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | MYH10, PDGFA, MPL | NR3C1 4364/4885PGR 157/4885MAPT 1935/4885 |
| US-20240391912-A1 | MORPHIC FORMS OF CFT7455 AND METHODS OF MANUFACTURE THEREOF | CLINT1, UGT1A1, DNM1 | NR3C1 2180/4885PGR 4351/4885MAPT 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.